1093.HK CSPC Pharmaceutical (HKSE) down pre-market before 25 Mar 2026 earnings: watch guidance

1093.HK stock opened at HK$8.45 and trades at HK$8.33 pre-market, down 5.34% as investors position ahead of CSPC Pharmaceutical Group Limited’s earnings due 25 Mar 2026. The sell-off follows heavier intraday volume of 99,301,497 shares against a 50-day average price of HK$9.69. Key figures to watch in the report are EPS 0.38, P/E 21.76, and guidance on oncology and metabolic partnerships. We use Meyka AI’s real-time signals and sector context to frame the earnings risk and potential upside for Hong Kong-listed CSPC on the HKSE.

Earnings preview for 1093.HK stock

CSPC reports on 25 Mar 2026 with market focus on revenue mix and R&D spend. Analysts will parse margins after fiscal 2024 net income fell 25.01% year-on-year and R&D rose by 9.35%.

Valuation and key metrics for 1093.HK stock

CSPC trades at P/E 21.76 and PB near 2.50, with a market cap of HK$94.46B. The balance sheet is strong: current ratio 2.24, net debt to EBITDA -1.05, and dividend yield about 2.90%, which supports income-focused investors.

Meyka Grade & technical snapshot for 1093.HK stock

Meyka AI rates 1093.HK with a score out of 100: 70.69 / 100, Grade B+, suggestion BUY. This grade factors S&P 500 and sector comparisons, financial growth, key metrics, and analyst signals. Technicals show RSI 34.78, MACD negative, and Bollinger lower band near HK$8.30, indicating short-term oversold pressure.

Catalysts and risks affecting 1093.HK stock

Positive catalysts include commercial updates on Duomeisu and the AstraZeneca licensing link reported by Investing.com. Major risks are softer domestic demand, slower EPS growth, and a high free cash flow multiple (P/FCF 55.87).

Earnings sensitivity and sector context for 1093.HK stock

Healthcare peers in Hong Kong show one-week weakness and average P/E about 28.70, so CSPC’s relative valuation is defensive. Expect the stock to react to margin guidance, product approvals, and partnership royalties in the near term.

Final Thoughts

Key takeaways: 1093.HK stock trades at HK$8.33 pre-market with heavy volume and clear downside pressure into the 25 Mar 2026 earnings release. Meyka AI’s forecast model projects a yearly price of HK$12.22, implying an upside of 46.66% versus the current price of HK$8.33. Shorter-term model points are HK$9.90 (monthly) and HK$11.70 (quarterly). These targets reflect product mix improvement and partnership revenue assumptions, not guarantees. On fundamentals CSPC shows strong cash coverage, low leverage, and a 2.90% dividend yield, but recent revenue and net income declines increase execution risk. Traders should watch management guidance, R&D cadence, and any AstraZeneca-related royalty updates. For deeper data and live alerts, see the Meyka stock page and real-time feed by Meyka AI as an AI-powered market analysis platform

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.